Prot #I3Y-US-X015: NU 18B04: MONARCH-PRECISION PROGRAM: A Prospective, Randomized, Open Label, Phase II Study of Abemaciclib Combined with Fulvestrant vs. Abemaciclib in Patients with Molecularly Defined Subtypes of Hormone-Receptor Positive (HR+), HER-2

Project: Research project

Project Details

StatusActive
Effective start/end date5/6/215/6/24

Funding

  • Lilly USA, LLC (Prot #I3Y-US-X015: NU 18B04)